ACTRN12614000007639已完成3 期
Improved treatment of Type 2 Diabetes by improving the splenic function and intestinal tract using ANIVINA, a novel drug composition based on naturally occurring bioactive compounds
guyen Van Toan0 个研究点目标入组 94 人开始时间: 2014年1月3日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 94
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 52 Years 至 85 Years（—）
- 性别
- All
入选标准
- •All participated patients aged between 52-85 years old, diagnosed with type 2 diabetes mellitus were informed about the purposes, methods and intended uses of the research. They were informed about what participation will involve and the risks as well as potential benefits explained. Moreover. the participants were allowed to withdraw themselves from participation at any time and for any reason without disadvantage and all information as well as data obtained about participants were confidential
排除标准
- •Out of age range of 52-85
研究者
相似试验
已完成
1 期
Treating To Target in Type 2 diabetesType 2 diabetesNutritional, Metabolic, EndocrineNon-insulin-dependent diabetes mellitusISRCTN51125379ovo Nordisk Limited (UK)700
进行中（未招募）
不适用
OPTIMISATION OF INSULIN TREATMENT OF TYPE 2 DIABETES MELLITUS BY TELECARE ASSISTANCE FOR SELF MONITORING OF BLOOD GLUCOSE ELEONOR STUDYTYPE 2 DIABETES MELLITUSMedDRA version: 6.1Level: HLTClassification code 10012602EUCTR2004-002731-62-ITAVENTIS PHARMA S.P.A.480
已完成
不适用
Salutogenic intervention for Diabetes Type 2Diabetes Mellitus Type 2 (T2DM)NL-OMON27447Wageningen University, Edema-Steernberg Foundation56
已完成
不适用
The control and prevention of type 2 diabetes by the inhibition of adipose tissue inflammation through DiacereiPatients aged 40â€65 years who had type 2 Diabetes for at least 2 years since diagnosis with a glycated haemoglobin (HbA1c) level of 7.5%â€10%type 2 Diabetes who had inadequate glycaemic controlTCTR20200820004/A35
进行中（未招募）
1 期
The DIAMOND for the Treatment of Type 2 Diabetes: Can Blood Triglycerides level be the predictor for therapy efficiency?Diabetes type 2 not controlled by oral medication.EUCTR2013-001003-36-ATMetacure Ltd.45